Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

NCT04999761 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT04999761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04999761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 1, 2021
Completion date
June 30, 2027
Enrollment
917 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumor, alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma